Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

Go back to Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Diversified Corporate Resources, Inc. (NASDAQ: IRD) Delayed: 3.51 -0.31 (8.12%)
Previous Close $3.82    52 Week High $0.02 
Open $3.79    52 Week Low $0.02 
Day High $3.83    P/E N/A 
Day Low $3.44    EPS $0.00 
Volume 799,082